An example blood cell lysis composition includes a buffer and a secondary alcohol ethoxylate at a concentration in the range of about 2.5 percent (%) to about 20% weight per volume (w/v). The secondary alcohol ethoxylate may include Tergitol™ TMN-100X or Tergitol™ 15-S-9. The composition may be configured to lyse at least 90% of blood cells in a blood sample.

It is disclosed a method for calibrating an electronic device for measuring the concentration of a biological compound, in particular bilirubin. The method comprises the step a) of performing (10) a plurality of reflectance measurements for each reference strip of a plurality of reference strips (110-1, 110-2, . . . 110-8) having respective predefined concentration values of the biological compound, the step b) of calculating (20), for each reference strip, a respective value of a statistical reflectance indicator as a function of the plurality of reflectance measurements, generating a plurality of values of the statistical reflectance indicator, the step c) of subdividing the plurality of values of the statistical reflectance indicator into at least two subsets (I, II, III), the step d) of interpolating (41) the values of the statistical reflectance indicator of each subset so as to generate an interpolation curve for each subset, the step e) of calculating (43), for each pair of interpolation curves relative to two adjacent subsets (I, II), a reflectance threshold value for which the difference of the reflectance values of the pair of interpolation curves is minimum, the step f) of selecting, for each interpolation curve, a portion delimited at least in part by the respective reflectance threshold values, said portion being associated with the respective plurality of values of the statistical reference indicator, and the step g) of generating (50) a calibration curve of the electronic device by combining the selected portions of the interpolation curves.

A method for measuring bilirubin concentration in a sample includes preparing a sensing element, where the sensing element may include a plurality of carbon dots, adding the sample to the sensing element, where the sample may include a plurality of bilirubin molecules, obtaining a first grayscale image of the sensing element under ultra-violet (UV) irradiation, irradiating visible light with a wavelength between 470 nm and 490 nm on the sensing element, obtaining a second grayscale image of the sensing element under ultra-violet (UV) irradiation, calculating a light intensity difference by calculating a difference between a first average light intensity of the first grayscale image and a second average light intensity of the second image, and determining the bilirubin concentration based on a correlation between the bilirubin concentration and the light intensity difference.

The invention relates to a method and a computer program for estimating a bilirubin level of a neonate, composed of the steps of: Acquiring a series of bilirubin levels estimated at different time points from a sample obtained from a neonate, Acquiring a plurality of covariates from the neonate, each composed of an information about a neonatal property, Providing a pre-defined bilirubin model function, wherein the bilirubin model function is configured to describe a time course of a bilirubin level of a neonate, Determining a plurality of model parameters of the bilirubin model function, wherein each model parameter is estimated from at least one covariate of the plurality of covariates and an associated population model parameter, Determining from the series of acquired bilirubin levels and the bilirubin model function with the determined model parameters an expected bilirubin level of the neonate for a time particularly later than a lastly acquired bilirubin level of the series of bilirubin levels.

The present invention relates generally to methods treating cholestatic liver disease by administering an ileal bile acid transporter inhibitor (IBAT inhibitor), wherein the treatment results in increased event-free survival (EFS). The present invention relates also to methods for providing a prediction of response to an IBAT inhibitor therapy for treatment of cholestatic liver disease by predicting EFS.

The present invention relates to a container comprising haemoglobin fractions, wherein said container comprising at least two compartments, wherein a first compartment comprises O2Hb (oxyhaemoglobin) and a second compartment comprises MetHb (methaemoglobin), optionally wherein O2Hb is stabilized. The invention also relates to a kit for determining the reliability of a CO-oximetry device, wherein said kit comprises said container and to a method for determining the reliability of a CO-oximetry device using said container.

Provided is a biomarker for diagnosing at-risk mental state (ARMS) that may include one or more selected from the group consisting of biopyrrin, cortisol, a KFLC or a fragment thereof, and a AFLC or a fragment thereof. Further provided is an ARMS diagnosis of a subject that may be performed quickly, easily, and accurately by measuring the amount of the biomarker for diagnosing ARMS in a biological sample.

The present disclosure relates generally to methods for using pexidartinib and related Risk Evaluation and Mitigation Strategy (REMS), while reducing the occurrence of hepatotoxic adverse events.

The present invention provides a method of measuring a component in blood, by which an amount of the component can be corrected accurately by measuring a hematocrit (Hct) value of the blood with high accuracy and high reliability and also provides a sensor used in the method. The method of measuring a component in blood using a biosensor comprising a first electrode system including a first working electrode on which at least an oxidoreductase that acts upon the component and a mediator are provided and a first counter electrode and a second working electrode on which the mediator is not provided. The first working electrode and the first counter electrode are used for obtaining the amount of the component and the second working electrode and the first working electrode are used for obtaining the amount of the blood cells.

A composition of a bilimbin stock and a method of preparation are provided. In one aspect of the invention, the composition includes a base solution. The composition further includes a carbonate salt. Additionally, the composition includes bilimbin. Furthermore, the composition includes human serum albumin